Navigation Links
DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
Date:1/6/2009

AUSTIN, Texas, Jan. 6 /PRNewswire/ -- DiFUSION Technologies, Inc., a medical device company targeting the orthopaedic market, today announced its corporate launch. The company will focus on reducing the rising incidence of Surgical Site Infections (SSIs) in spinal surgeries.

"In large studies, five out of 100 spine cases result in SSIs often leading to second surgeries that are extremely costly and difficult for the patient," said Dr. Matthew Geck, founder and board member of DiFUSION and leading orthopaedic surgeon in Austin, Texas. "DiFUSION will release a medical device in 2009 capable of killing 650 types of bacteria including antibiotic-resistant bacteria such as MRSA (also known as "Superbugs") in the local surgical wound for up to four weeks following surgery."

DiFUSION's founding and scientific board members comprise a team of recognized physicians in the field of spinal, biochemical and genetic research, and senior executives hold extensive experience in spinal product development and clinical studies.

"DiFUSION's solution may not only improve infection ratios, the 'super silicate' technology will also affect the bone remodeling sequence in a potentially positive fashion," said Dr. Peter Whang, a member of DiFUSION's scientific advisory board and an Assistant Professor in the Department of Orthopaedics and Rehabilitation at the Yale University School of Medicine in New Haven, Connecticut. "SSIs are also a focus of quality improvement as part of the 'pay for performance' initiative for hospitals, insurers and physicians."

"The controlled delivery of cationic elements possible with our 'super silicate' open multiple promising applications from infection control to bone growth," said Dr. Gary Ghiselli, chair of the DiFUSION scientific advisory board and a board-certified orthopaedic surgeon in Denver, Colorado, who exclusively focuses on spine and complex deformity and degenerative disorders of the cervical spine. "Hospital born surgical site infections place a $5 billion annual burden on the U.S. health care system. Our technology has the potential to save $150 million in the spine segment alone, a tremendous savings for the health care industry."

DiFUSION is funded by angel investors, and the company will be seeking a second round of funding for marketing and sales support in order to roll out the medical device on a nationwide basis. Current investors are expected to participate in the upcoming round.

About DiFUSION Executives / Scientific Advisors:

Dr. Matthew Geck - DiFUSION Founder and Board Member. A leading board-certified orthopaedic surgeon in Austin, Texas, specifically focused on spine and scoliosis surgery and pediatric cervical. Dr. Geck is a member of the Scoliosis Research Society, where he participates in the Pediatric Spine Surgery Mission to Cali, Colombia, and is the founder of the Spinal Deformity Foundation.

Dr. Peter Whang - DiFUSION Scientific Advisory Board Member. Assistant Professor in the Department of Orthopaedics and Rehabilitation at the Yale University School of Medicine, New Haven, Connecticut. Received an MD from the Duke University School of Medicine and a B.S. from Harvard University in Biochemistry. Widely read author on spinal infections, biological materials and bone graft substitutes.

Dr. Gary Ghiselli - DiFUSION Scientific Advisory Board Chair. A board-certified orthopaedic surgeon in Denver, Colorado, exclusively focused on spine and complex deformity and degenerative disorders of the cervical spine. Received an MD from the University of Texas, Southwestern Medical School and a B.S. from UCLA in Biochemistry.

Dr. Hyun Bae - DiFUSION Scientific Advisory Board Member. A board-certified orthopaedic surgeon in Santa Monica, California, specializing in minimally invasive microsurgery and the treatment of cervical and lumbar spinal disease. Received an MD from the Yale School of Medicine and a B.S. from Columbia University in Biomechanics.

Dr. Nitin Bhatia - DiFUSION Scientific Advisory Board Member. A board-certified orthopaedic surgeon and Assistant Professor of Clinical Orthopaedic Surgery at the University of California, Irvine. Received an MD from Baylor College of Medicine and a B.S. from Stanford University in Science and Biology.

Dr. John Stokes - DiFUSION Scientific Advisory Board Member. A board-certified neurological surgeon in Austin, Texas, with expertise in cranial neurosurgery and complex spine neurosurgery. Developed the Artificial Lumbar Disc Training Center at Brackenridge Hospital in Austin, Texas.

Derrick Johns - DiFUSION President and CEO. Has a decade of experience in the spine industry and has launched over a dozen products totaling more than $500 million in annual sales, such as the Array Spinal System and the Sequoia Pedicle Screw System. Received his B.A. from Hamilton College after completing a four-year duty with the US Marine Corps.

Steve Vandegrift - DiFUSION Chairman. 25-year veteran in venture capital and investment banking for technology companies. Owner of an investment firm assisting companies in fund-raising, new business development, mergers and acquisitions. Most recently managing director of Techxas Ventures and current member of the Federal Reserve Board.

About DiFUSION Technologies

DiFUSION Technologies, located in Austin, Texas, is a medical device company that develops silver-based antimicrobial solutions for the orthopaedic spinal market to reduce Surgical Site Infections (SSIs) in spinal surgery. DiFUSION will release a medical device in 2009 capable of mitigating 650 types of bacteria, including MRSA, up to four weeks postoperatively, thereby drastically reducing hospital acquired infections or SSIs. DiFUSION is funded by angel investors, and the company will be seeking a second round of funding for marketing and sales support in order to roll out the medical device on a nationwide basis. Current investors are expected to participate in the upcoming round. For more information about DiFUSION Technologies, visit www.difusiontech.com.


'/>"/>
SOURCE DiFUSION Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... RawTrition now brings you BioEnergy which is a powder ... , RawTrition is taking nutrients to the next level! The superfoods ... its raw form (unlike the synthetically made options that are on the market). , ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology: